Your browser doesn't support javascript.
Cost-Effectiveness of Sotrovimab for the Treatment of Mild-to-Moderate COVID-19 in Patients at High Risk of Disease Progression in Italy
Value Health ; 25(12):S147, 2022.
Article in English | PubMed Central | ID: covidwho-2159394

Full text: Available Collection: Databases of international organizations Database: PubMed Central Type of study: Experimental Studies / Prognostic study Language: English Journal: Value Health Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: Databases of international organizations Database: PubMed Central Type of study: Experimental Studies / Prognostic study Language: English Journal: Value Health Year: 2022 Document Type: Article